Question

When can a resident self-administer drugs?

a)When the medical director says it's ok
b)When the family says it's ok
c) Never
d)When the IDT (Interdisciplinary Team) says it's ok

Answer 1

The FDA can halt gene therapy at any stage, including at IND application submission, during clinical trials, and after manufacturing and marketing, which is when all responses are correct.

Step-by-step explanation:

The FDA can halt the development or use of gene therapy at various points in its progression, including on submission of an IND application, during clinical trials, and after manufacturing and marketing of the approved therapy. The correct answer is d. all of the answers are correct. The FDA has the authority and responsibility to ensure the safety and efficacy of gene therapies at all stages of development. This includes the initial Investigational New Drug (IND) application, a critical juncture where safety and planned protocols are evaluated, during clinical trials where safety and efficacy data are closely monitored, and after a product is on the market to ensure ongoing safety and effectiveness.